Lesley McGee1, Sopio Chochua1, Zhongya Li2, Saundra Mathis2, Joy Rivers1, Benjamin Metcalf1, Alison Ryan3, Nisha Alden4, Monica M Farley5,6, Lee H Harrison7, Paula Snippes Vagnone8, Ruth Lynfield8, Chad Smelser9, Alison Muse10, Ann R Thomas11, Stephanie Schrag1, Bernard W Beall1. 1. Respiratory Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. 2. IHRC Inc, Contractor to Centers for Disease Control and Prevention, Atlanta, Georgia, USA. 3. California Emerging Infections Program, Oakland, California, USA. 4. Colorado Department of Public Health and Environment, Denver, Colorado, USA. 5. Emory University School of Medicine, Atlanta, Georgia, USA. 6. Atlanta Veterans Affairs Medical Center, Atlanta, Georgia, USA. 7. Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA. 8. Minnesota Department of Health, Saint Paul, Minnesota, USA. 9. New Mexico Department of Public Health, Santa Fe, New Mexico, USA. 10. New York State Department of Health, Albany, New York, USA. 11. Oregon Department of Human Services, Portland, Oregon, USA.
Abstract
BACKGROUND: Group B Streptococcus (GBS) is a leading cause of neonatal sepsis and meningitis and an important cause of invasive infections in pregnant and nonpregnant adults. Vaccines targeting capsule polysaccharides and common proteins are under development. METHODS: Using whole genome sequencing, a validated bioinformatics pipeline, and targeted antimicrobial susceptibility testing, we characterized 6340 invasive GBS isolates recovered during 2015-2017 through population-based Active Bacterial Core surveillance (ABCs) in 8 states. RESULTS: Six serotypes accounted for 98.4% of isolates (21.8% Ia, 17.6% V, 17.1% II, 15.6% III, 14.5% Ib, 11.8% IV). Most (94.2%) isolates were in 11 clonal complexes (CCs) comprised of multilocus sequence types identical or closely related to sequence types 1, 8, 12, 17, 19, 22, 23, 28, 88, 452, and 459. Fifty-four isolates (0.87%) had point mutations within pbp2x associated with nonsusceptibility to 1 or more β-lactam antibiotics. Genes conferring resistance to macrolides and/or lincosamides were found in 56% of isolates; 85.2% of isolates had tetracycline resistance genes. Two isolates carrying vanG were vancomycin nonsusceptible (minimum inhibitory concentration = 2 µg/mL). Nearly all isolates possessed capsule genes, 1-2 of the 3 main pilus gene clusters, and 1 of 4 homologous alpha/Rib family determinants. Presence of the hvgA virulence gene was primarily restricted to serotype III/CC17 isolates (465 isolates), but 8 exceptions (7 IV/CC452 and 1 IV/CC17) were observed. CONCLUSIONS: This first comprehensive, population-based quantitation of strain features in the United States suggests that current vaccine candidates should have good coverage. The β-lactams remain appropriate for first-line treatment and prophylaxis, but emergence of nonsusceptibility warrants ongoing monitoring. Published by Oxford University Press for the Infectious Diseases Society of America 2020.
BACKGROUND: Group B Streptococcus (GBS) is a leading cause of neonatal sepsis and meningitis and an important cause of invasive infections in pregnant and nonpregnant adults. Vaccines targeting capsule polysaccharides and common proteins are under development. METHODS: Using whole genome sequencing, a validated bioinformatics pipeline, and targeted antimicrobial susceptibility testing, we characterized 6340 invasive GBS isolates recovered during 2015-2017 through population-based Active Bacterial Core surveillance (ABCs) in 8 states. RESULTS: Six serotypes accounted for 98.4% of isolates (21.8% Ia, 17.6% V, 17.1% II, 15.6% III, 14.5% Ib, 11.8% IV). Most (94.2%) isolates were in 11 clonal complexes (CCs) comprised of multilocus sequence types identical or closely related to sequence types 1, 8, 12, 17, 19, 22, 23, 28, 88, 452, and 459. Fifty-four isolates (0.87%) had point mutations within pbp2x associated with nonsusceptibility to 1 or more β-lactam antibiotics. Genes conferring resistance to macrolides and/or lincosamides were found in 56% of isolates; 85.2% of isolates had tetracycline resistance genes. Two isolates carrying vanG were vancomycin nonsusceptible (minimum inhibitory concentration = 2 µg/mL). Nearly all isolates possessed capsule genes, 1-2 of the 3 main pilus gene clusters, and 1 of 4 homologous alpha/Rib family determinants. Presence of the hvgA virulence gene was primarily restricted to serotype III/CC17 isolates (465 isolates), but 8 exceptions (7 IV/CC452 and 1 IV/CC17) were observed. CONCLUSIONS: This first comprehensive, population-based quantitation of strain features in the United States suggests that current vaccine candidates should have good coverage. The β-lactams remain appropriate for first-line treatment and prophylaxis, but emergence of nonsusceptibility warrants ongoing monitoring. Published by Oxford University Press for the Infectious Diseases Society of America 2020.
Entities:
Keywords:
capsular serotypes; resistance determinants; surface protein distributions; β-lactam nonsusceptibility
Authors: Louise K Francois Watkins; Lesley McGee; Stephanie J Schrag; Bernard Beall; Jennifer Hudson Jain; Tracy Pondo; Monica M Farley; Lee H Harrison; Shelley M Zansky; Joan Baumbach; Ruth Lynfield; Paula Snippes Vagnone; Lisa A Miller; William Schaffner; Ann R Thomas; James P Watt; Susan Petit; Gayle E Langley Journal: JAMA Intern Med Date: 2019-04-01 Impact factor: 21.873
Authors: Srinivas Acharya Nanduri; Susan Petit; Chad Smelser; Mirasol Apostol; Nisha B Alden; Lee H Harrison; Ruth Lynfield; Paula S Vagnone; Kari Burzlaff; Nancy L Spina; Elizabeth M Dufort; William Schaffner; Ann R Thomas; Monica M Farley; Jennifer H Jain; Tracy Pondo; Lesley McGee; Bernard W Beall; Stephanie J Schrag Journal: JAMA Pediatr Date: 2019-03-01 Impact factor: 16.193
Authors: Nina M van Sorge; Darin Quach; Michael A Gurney; Paul M Sullam; Victor Nizet; Kelly S Doran Journal: J Infect Dis Date: 2009-05-15 Impact factor: 5.226
Authors: Samira Dahesh; Mary E Hensler; Nina M Van Sorge; Robert E Gertz; Stephanie Schrag; Victor Nizet; Bernard W Beall Journal: Antimicrob Agents Chemother Date: 2008-06-09 Impact factor: 5.191
Authors: Allison N Dammann; Anna B Chamby; Francisco J Gonzalez; Molly E Sharp; Karina Flores; Ifrah Shahi; Sophia Dongas; Thomas A Hooven; Adam J Ratner Journal: J Infect Dis Date: 2022-06-01 Impact factor: 7.759
Authors: Yuan Li; Samuel Dominguez; Srinivas A Nanduri; Joy Rivers; Saundra Mathis; Zhongya Li; Lesley McGee; Sopio Chochua; Benjamin J Metcalf; Chris A Van Beneden; Bernard Beall; Lisa Miller Journal: J Infect Dis Date: 2022-05-16 Impact factor: 7.759
Authors: M Belén Cubria; Luis Alberto Vega; William C Shropshire; Misu A Sanson; Brittany J Shah; Shrijana Regmi; Marcia Rench; Carol J Baker; Anthony R Flores Journal: Antimicrob Agents Chemother Date: 2021-10-11 Impact factor: 5.938
Authors: Miwako Kobayashi; Lesley McGee; Sopio Chochua; Mirasol Apostol; Nisha B Alden; Monica M Farley; Lee H Harrison; Ruth Lynfield; Paula Snippes Vagnone; Chad Smelser; Alison Muse; Ann R Thomas; Li Deng; Benjamin J Metcalf; Bernard W Beall; Stephanie J Schrag Journal: Open Forum Infect Dis Date: 2020-12-21 Impact factor: 3.835